SEOUL -- South Korea's medicine maker Hyundai Pharma has forged a partnership with an artificial intelligence-based drug development company, to jointly research and develop new innovative medicines. AI-based drug development does not require many human researchers and can save time and costs.
Hyundai Pharm said in a statement on January 20 that it has signed a cooperation agreement with Pharminogen, an AI-based biopharmaceutical company. Pharminogen uses AI deep learning technology to develop novel drugs.
The AI drug development technique incorporates big data of medical records and substances for drugs. Through deep learning, AI sorts and categorizes data to come up with new products that can efficiently target specific diseases or symptoms.
South Korea's biopharmaceutical industry has adopted AI-based drug development. In June 2020, drug maker Boryung Pharmaceutical partnered with Pharminogen for AI-based medicine development. In December Boryung joined hands with Quantum Intelligence, an AI-based novel drug maker, to develop customized treatments and diagnosis technology using Quantum Intelligence's AI medicine development platform.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.